Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiviral Agents | 14 | 2021 | 369 | 4.070 |
Why?
|
| Hepatitis C | 12 | 2022 | 186 | 4.020 |
Why?
|
| Hepatitis C, Chronic | 8 | 2020 | 95 | 2.590 |
Why?
|
| Hepacivirus | 7 | 2022 | 137 | 2.090 |
Why?
|
| Gastroenterology | 4 | 2021 | 162 | 1.170 |
Why?
|
| Lactulose | 1 | 2023 | 22 | 0.790 |
Why?
|
| Hepatic Encephalopathy | 1 | 2023 | 35 | 0.790 |
Why?
|
| Liver Diseases | 2 | 2016 | 249 | 0.710 |
Why?
|
| Ribavirin | 2 | 2013 | 37 | 0.700 |
Why?
|
| Internship and Residency | 4 | 2021 | 1120 | 0.680 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2021 | 6 | 0.670 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2021 | 20 | 0.670 |
Why?
|
| Off-Label Use | 2 | 2014 | 20 | 0.500 |
Why?
|
| Liver Cirrhosis | 5 | 2017 | 288 | 0.490 |
Why?
|
| Interferon-alpha | 2 | 2013 | 191 | 0.460 |
Why?
|
| Hepatitis B, Chronic | 1 | 2015 | 36 | 0.450 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 532 | 0.440 |
Why?
|
| Informed Consent | 2 | 2020 | 281 | 0.440 |
Why?
|
| Liver Transplantation | 5 | 2023 | 1234 | 0.420 |
Why?
|
| Viral Load | 2 | 2021 | 162 | 0.420 |
Why?
|
| Polyethylene Glycols | 2 | 2013 | 382 | 0.400 |
Why?
|
| Medicaid | 1 | 2017 | 276 | 0.400 |
Why?
|
| Interferons | 1 | 2014 | 114 | 0.400 |
Why?
|
| Drug Discovery | 1 | 2013 | 120 | 0.350 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 268 | 0.350 |
Why?
|
| Humans | 31 | 2023 | 97893 | 0.340 |
Why?
|
| Biliary Tract Diseases | 1 | 2011 | 36 | 0.330 |
Why?
|
| Resource Allocation | 1 | 2011 | 65 | 0.330 |
Why?
|
| Health Care Rationing | 1 | 2011 | 85 | 0.320 |
Why?
|
| Curriculum | 4 | 2021 | 633 | 0.320 |
Why?
|
| Patient Participation | 1 | 2012 | 246 | 0.320 |
Why?
|
| Treatment Outcome | 8 | 2021 | 9682 | 0.280 |
Why?
|
| United States | 8 | 2021 | 8183 | 0.220 |
Why?
|
| Tissue and Organ Procurement | 1 | 2010 | 423 | 0.210 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 539 | 0.190 |
Why?
|
| Proline | 2 | 2013 | 51 | 0.180 |
Why?
|
| Liver Neoplasms | 2 | 2020 | 826 | 0.180 |
Why?
|
| Social Stigma | 1 | 2022 | 95 | 0.170 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 95 | 0.170 |
Why?
|
| United States Food and Drug Administration | 2 | 2014 | 164 | 0.170 |
Why?
|
| Viremia | 1 | 2021 | 56 | 0.170 |
Why?
|
| Oligopeptides | 2 | 2013 | 206 | 0.160 |
Why?
|
| Azathioprine | 1 | 2021 | 127 | 0.160 |
Why?
|
| Donor Selection | 1 | 2021 | 86 | 0.160 |
Why?
|
| Prednisone | 1 | 2021 | 251 | 0.160 |
Why?
|
| Beneficence | 1 | 2020 | 36 | 0.160 |
Why?
|
| Drug Therapy, Combination | 2 | 2014 | 762 | 0.150 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 993 | 0.150 |
Why?
|
| Risk Assessment | 4 | 2021 | 2580 | 0.150 |
Why?
|
| End Stage Liver Disease | 2 | 2017 | 77 | 0.140 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 480 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2021 | 370 | 0.140 |
Why?
|
| Ethics, Medical | 1 | 2021 | 292 | 0.140 |
Why?
|
| Female | 12 | 2021 | 51463 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2023 | 660 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 872 | 0.130 |
Why?
|
| Legislation, Drug | 1 | 2017 | 7 | 0.130 |
Why?
|
| Tissue Donors | 1 | 2021 | 581 | 0.130 |
Why?
|
| Rifamycins | 1 | 2016 | 7 | 0.120 |
Why?
|
| Hepatorenal Syndrome | 1 | 2016 | 9 | 0.120 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2017 | 29 | 0.120 |
Why?
|
| Paracentesis | 1 | 2016 | 12 | 0.120 |
Why?
|
| Coinfection | 2 | 2015 | 72 | 0.120 |
Why?
|
| Flaviviridae Infections | 1 | 2015 | 1 | 0.120 |
Why?
|
| GB virus C | 1 | 2015 | 1 | 0.120 |
Why?
|
| Ascites | 1 | 2016 | 55 | 0.120 |
Why?
|
| Internal Medicine | 2 | 2016 | 336 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 1013 | 0.120 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 87 | 0.120 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2015 | 20 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 658 | 0.110 |
Why?
|
| Deficiency Diseases | 1 | 2015 | 12 | 0.110 |
Why?
|
| Waiting Lists | 1 | 2017 | 237 | 0.110 |
Why?
|
| Middle Aged | 8 | 2021 | 29352 | 0.110 |
Why?
|
| Career Choice | 1 | 2016 | 161 | 0.110 |
Why?
|
| Comorbidity | 2 | 2015 | 1032 | 0.110 |
Why?
|
| Liver Failure | 1 | 2015 | 72 | 0.110 |
Why?
|
| Male | 10 | 2021 | 46995 | 0.110 |
Why?
|
| Zinc | 1 | 2015 | 99 | 0.110 |
Why?
|
| Drug and Narcotic Control | 1 | 2014 | 8 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 71 | 0.100 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2014 | 38 | 0.100 |
Why?
|
| Time Factors | 4 | 2021 | 5555 | 0.100 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 836 | 0.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 68 | 0.100 |
Why?
|
| Drug Design | 1 | 2014 | 135 | 0.100 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 196 | 0.100 |
Why?
|
| Hepatitis B | 1 | 2014 | 78 | 0.100 |
Why?
|
| Drug Industry | 1 | 2014 | 57 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2016 | 985 | 0.100 |
Why?
|
| Disease Management | 1 | 2015 | 377 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 2008 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 446 | 0.090 |
Why?
|
| Truth Disclosure | 1 | 2012 | 75 | 0.090 |
Why?
|
| Algorithms | 2 | 2020 | 2001 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 360 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 321 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1946 | 0.090 |
Why?
|
| Physicians | 1 | 2018 | 685 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 449 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2016 | 863 | 0.080 |
Why?
|
| Recurrence | 1 | 2013 | 1254 | 0.080 |
Why?
|
| Hospitalization | 1 | 2016 | 982 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2011 | 321 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2015 | 3202 | 0.080 |
Why?
|
| Decision Trees | 1 | 2020 | 63 | 0.080 |
Why?
|
| Animals | 2 | 2023 | 28910 | 0.080 |
Why?
|
| Mice | 1 | 2023 | 12707 | 0.070 |
Why?
|
| Age Factors | 1 | 2013 | 1960 | 0.070 |
Why?
|
| Precision Medicine | 1 | 2013 | 498 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 1108 | 0.070 |
Why?
|
| RNA, Viral | 2 | 2021 | 287 | 0.070 |
Why?
|
| Critical Illness | 1 | 2011 | 360 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2012 | 580 | 0.070 |
Why?
|
| Prognosis | 1 | 2015 | 4112 | 0.060 |
Why?
|
| Critical Care | 1 | 2011 | 462 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 7386 | 0.060 |
Why?
|
| Aged | 5 | 2016 | 21701 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 601 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2021 | 1094 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 1125 | 0.050 |
Why?
|
| Mass Screening | 2 | 2022 | 745 | 0.050 |
Why?
|
| Adult | 4 | 2021 | 29453 | 0.050 |
Why?
|
| HIV Infections | 1 | 2013 | 1018 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2023 | 147 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2023 | 101 | 0.050 |
Why?
|
| Feces | 1 | 2023 | 387 | 0.040 |
Why?
|
| Risk Factors | 3 | 2021 | 6224 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 1103 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 304 | 0.030 |
Why?
|
| Chicago | 1 | 2022 | 1513 | 0.030 |
Why?
|
| Graft Survival | 1 | 2021 | 994 | 0.030 |
Why?
|
| Midodrine | 1 | 2016 | 5 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2021 | 520 | 0.030 |
Why?
|
| Vasoconstrictor Agents | 1 | 2016 | 71 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 68 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2016 | 117 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2015 | 192 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 301 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 155 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 724 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 301 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 140 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 920 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2015 | 174 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 889 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 424 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 523 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 518 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 902 | 0.020 |
Why?
|
| Prevalence | 1 | 2017 | 1384 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1009 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 2222 | 0.020 |
Why?
|
| Length of Stay | 1 | 2016 | 869 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1995 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 1776 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 569 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 2896 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2016 | 10947 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 2040 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 1609 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 2666 | 0.020 |
Why?
|
| Phylogeny | 1 | 2015 | 1339 | 0.020 |
Why?
|
| Family Health | 1 | 2009 | 156 | 0.020 |
Why?
|
| Health Education | 1 | 2009 | 109 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 4023 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 7504 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 10078 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 2555 | 0.010 |
Why?
|